1Barentsz JO, Richenberg J, Clements R, et al. ESUR prostateMR guidelines 2012[J].Eur Radiol, 2012,22(4):746-757.
2Hamoen EH, de Rooij M, Witjes JA, et al. Use of the prostateimaging reporting and data system (PI-RADS) for prostatecancer detection with multiparametric magnetic resonanceimaging: a diagnostic meta-analysis[J].Eur Urol, 2014, Inpress.
3American College of Radiology. Prostate imaging and reportand data system (PI-RADS) [EB/OL].http://www.acr.org/Quality-Safety/Resources/PIRADS.
4Turkbey B, Choyke PL. Multiparametric MRI and prostatecancer diagnosis and risk stratification[J].Curr Opin Urol,2012,22(4):310-315.
5Rouvi^re 0, Hartman RP, Lyonnet D. Prostate MR imaging athigh-field strength: evolution or revolution[J].Eur Radiol,2006,16(2):276-284.
6Johnston R, Wong LM, Warren A, et al. The role of 1.5 Teslamagnetic resonance imaging in staging prostate cancer[J].ANZ J Surg, 2013,83(4):234-238.
7Kim BS, Kim TH, Kwon TG, et al. Comparison of pelvicphased-array versus endorectal coil magnetic resonanceimaging at 3 Tesla for local staging of prostate cancer[J].Yonsei Med J, 2012,53(3):550-556.
8Haider MA, Krieger A, Elliott C, et al. Prostate imaging:evaluation of a reusable two-channel endorectal receiver coilfor MR imaging at 1.5 T[J].Radiology, 2014, 270(2):556-565.
9Comelis F,Rigou G, Le Bras Y, et al. Real-timecontrast-enhanced transrectal US-guided prostate biopsy:diagnostic accuracy in men with previously negative biopsyresults and positive MR imaging findings[J].Radiology, 2013,269(1):159-166.
10Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonanceimaging for the detection, localisation, and characterisation ofprostate cancer: recommendations from a Europeanconsensus meeting[J].Eur Urol, 2011,59(4):477-494.
3MeNeal JE. Normal and pathologic anatomy of the prostate[J]. Urol,1981,17(3):11-16.
4Fergus V , Hedvig H , Antje E , et al . Brachytherapy for prostate cancer: Endorectal MR Imaging of local treatment - related changes [J]. Radiology, 2001,219(3) :817 -821.
5Jager GJ,Ruijter ET, van de Kaa CA, et al. Dynamic Turbo FLASH subtraction technique for contrast - enhanced MR imaging of the prostate :correlation with histopathologic results[J]. Radiology, 1997,203(3) :645 -652.
6Bigler SA , Deering RE , Brawer MK . Comparison of microscopic vascularity in benign and malignant prostate tissue[ J ]. Hum Pathol,1993,24 ( 2 ) :220 - 226.
7Hawighorst H, Knapstein PG, Knopp MV, et al. Cervical carcinoma:standard and pharmacokinetic analysis of time - intensity curve for assessment of tumors angiogenesis and patient survival[J]. MAGMA, 1999,8(1) :55 -62.
8Checkley D, Tessier J, Kendrew J, et al. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signaling inhibitor, in PC -3 prostate tumours[J]. Br J Cancer, 2003,89(10): 1889 - 1895.
9杨光华．病理学[M]．第5版．北京：人民卫生出版社，2003．80-121．
10Rouviere O , Raudrant A , Ecochard R , et al . Characterization of time - enhancement curves of benign and malignant prostate tissue at dynamic MR imaging[J]. Eur Radiol, 2003,13 (5) :931 - 942.
